STOCK TITAN
  1. Home
  2. RO

RO (RO) Stock Price, News & Analysis

RO
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
0 2 sessions, November 17, 2015 to January 27, 2016
Largest daily move
-4.6% close of January 27, 2016

Company Description

RO has declined 4.6% over the past month. The last closing price was $237.13.

This page collects what Stock Titan holds for RO, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
-
-
Last updated:
-4.6%
Performance 1 month
-
Market Cap
-
Shares outstanding

RO (RO) closed at $237.13 on January 27, 2016. Over the past month, the price has lost 4.6%.

See what a $1,000 investment in RO would be worth today

RO Metrics & Rankings

Month to date
-4.6%
View ranking
YTD
-4.6%
View ranking

Price returns through January 27, 2016. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Latest News

View All
0.00%

Genentech Provides Update on Tominersen Program in Manifest Huntington's Disease

0.00%

Pivotal Phase III Study Shows Genentech’s Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning

clinical trial
0.00%

New 2-Year Data Show Genentech’s Evrysdi (risdiplam) Continues to Demonstrate Improvement or Maintenance of Motor Function in People Aged 2-25 With Type 2 or Type 3 Spinal Muscular Atrophy (SMA)

0.00%

Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia

clinical trial covid-19
0.00%

Genentech Provides Update on Tecentriq U.S. Indication in Prior-Platinum Treated Metastatic Bladder Cancer

0.00%

Genentech’s Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition

fda approval
0.00%

Genentech Announces Results From Evrysdi (risdiplam) Study in Infants With Type 1 Spinal Muscular Atrophy (SMA) Published in New England Journal of Medicine

0.00%

New Phase III Data Show Genentech’s Faricimab Is the First Investigational Injectable Eye Medicine to Extend Time Between Treatments up to Four Months in Two Leading Causes of Vision Loss, Potentially Reducing Treatment Burden for Patients

clinical trial
0.00%

Genentech’s Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular Degeneration

clinical trial
0.00%

FDA Grants Priority Review to Genentech’s Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease

fda approval

RO has 10 recent news articles. Key topics include clinical trial, covid-19, fda approval. View all RO news →

SEC Filings

View All

No SEC filings available for RO.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

Frequently Asked Questions

What is the current quoted price of RO (RO)?

The current quoted price of RO (RO) is $237.13 as of September 5, 2024.